The global burden of hepatitis C

被引:1015
作者
Lavanchy, Daniel [1 ]
机构
[1] WHO, HSE, EPR, BDP, CH-1211 Geneva 27, Switzerland
关键词
cirrhosis; epidemiology; HCC; HCV; hepatitis C; prevention; liver cancer; ALPHA-2B PLUS RIBAVIRIN; CHRONIC LIVER-DISEASE; INJECTION-DRUG USERS; COST-EFFECTIVENESS; VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; SUSTAINED RESPONSE; HUMAN-IMMUNODEFICIENCY; HISTOLOGIC IMPROVEMENT; CIGARETTE-SMOKING;
D O I
10.1111/j.1478-3231.2008.01934.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C is of concern both to industrialized and developing countries. Preliminary unpublished estimates of the global burden of disease (GBD) attributable to HCV-related chronic liver disease seem to be substantial. Therefore, the reduction of global mortality and morbidity related to chronic hepatitis C should be a concern to public health authorities, and primary, secondary and tertiary prevention activities should be implemented and monitored in each country, with precise targets set to be reached. In order to decide on national health policies, there is a need to estimate the burden of disease, globally, regionally and nationally. To evaluate the GBD, three components have to be assessed: 1) The global, regional and national burden of morbidity and mortality associated with HCV infection, based on prevalence, incidence, transmission and economics; 2) The natural history of HCV infection, including 'healthy individuals'; and 3) The areas for which more research is needed. A working group was created to assist the World Health organization (WHO) in estimating the GBD associated with HCV infection.
引用
收藏
页码:74 / 81
页数:8
相关论文
共 88 条
  • [41] Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C
    Hézode, C
    Roudot-Thoraval, F
    Nguyen, S
    Grenard, P
    Julien, B
    Zafrani, ES
    Pawlostky, JM
    Dhumeaux, D
    Lotersztajn, S
    Mallat, A
    [J]. HEPATOLOGY, 2005, 42 (01) : 63 - 71
  • [42] Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C
    Hickman, IJ
    Clouston, AD
    Macdonald, GA
    Purdie, DM
    Prins, JB
    Ash, S
    Jonsson, JR
    Powell, EE
    [J]. GUT, 2002, 51 (01) : 89 - 94
  • [43] Hepatitis C: The clinical spectrum of disease
    Hoofnagle, JH
    [J]. HEPATOLOGY, 1997, 26 (03) : S15 - S20
  • [44] Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
    Hourigan, LF
    Macdonald, GA
    Purdie, D
    Whitehall, VLJ
    Shorthouse, C
    Clouston, A
    Powell, EE
    [J]. HEPATOLOGY, 1999, 29 (04) : 1215 - 1219
  • [45] Global burden of disease (GBD) for hepatitis C
    Hutin, Y
    Kitler, ME
    Dore, GJ
    Perz, JF
    Armstrong, GL
    Dusheiko, G
    Ishibashi, H
    Grob, P
    Kew, M
    Marcellin, P
    Seeff, LB
    Beutels, P
    Nelson, C
    Stein, C
    Zurn, P
    Clifford, G
    Vranckx, R
    Alberti, A
    Hallaj, ZS
    Hadler, S
    Lavanchy, D
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (01) : 20 - 29
  • [46] Hutin YJF, 1999, B WORLD HEALTH ORGAN, V77, P787
  • [47] Kane A, 1999, B WORLD HEALTH ORGAN, V77, P801
  • [48] Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
    Kenny-Walsh, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (16) : 1228 - 1233
  • [49] KEW MC, 1998, VIRAL HEPATITIS, V4, P259
  • [50] KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease - Foreword
    Lameire, Norbert
    Eknoyan, Garabed
    [J]. KIDNEY INTERNATIONAL, 2008, 73 : S1 - S2